SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 316 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q1 2018. The put-call ratio across all filers is 1.45 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $19,606,930 | -1.0% | 711,169 | +8.0% | 0.02% | +4.5% |
| Q2 2023 | $19,800,552 | -17.3% | 658,701 | -0.3% | 0.02% | -18.5% |
| Q1 2023 | $23,938,465 | -2.1% | 660,736 | -3.7% | 0.03% | -3.6% |
| Q4 2022 | $24,463,841 | -7.0% | 685,838 | -11.8% | 0.03% | -9.7% |
| Q3 2022 | $26,317,000 | +16.0% | 777,469 | -0.9% | 0.03% | +19.2% |
| Q2 2022 | $22,694,000 | -15.7% | 784,720 | -6.5% | 0.03% | -3.7% |
| Q1 2022 | $26,919,000 | +9.0% | 839,602 | -0.9% | 0.03% | +17.4% |
| Q4 2021 | $24,705,000 | +6.9% | 847,243 | -2.3% | 0.02% | 0.0% |
| Q3 2021 | $23,116,000 | +17.5% | 866,750 | +35.7% | 0.02% | +21.1% |
| Q2 2021 | $19,671,000 | +78.5% | 638,878 | +51.8% | 0.02% | +72.7% |
| Q1 2021 | $11,021,000 | +2.3% | 420,947 | -1.6% | 0.01% | -8.3% |
| Q4 2020 | $10,768,000 | +6.1% | 427,954 | -12.1% | 0.01% | -7.7% |
| Q3 2020 | $10,146,000 | +1453.8% | 486,845 | +1670.7% | 0.01% | +1200.0% |
| Q2 2020 | $653,000 | -29.0% | 27,494 | -46.3% | 0.00% | 0.0% |
| Q1 2020 | $920,000 | +36.3% | 51,160 | +79.7% | 0.00% | 0.0% |
| Q4 2019 | $675,000 | +13.6% | 28,468 | +31.7% | 0.00% | 0.0% |
| Q3 2019 | $594,000 | +786.6% | 21,623 | +971.0% | 0.00% | – |
| Q2 2019 | $67,000 | -65.5% | 2,019 | -63.5% | 0.00% | – |
| Q1 2019 | $194,000 | -22.4% | 5,526 | -26.7% | 0.00% | -100.0% |
| Q4 2018 | $250,000 | -31.5% | 7,536 | +4.1% | 0.00% | 0.0% |
| Q3 2018 | $365,000 | +46.6% | 7,240 | +74.0% | 0.00% | 0.0% |
| Q2 2018 | $249,000 | +51.8% | 4,160 | +15.9% | 0.00% | – |
| Q1 2018 | $164,000 | +50.5% | 3,590 | +30.8% | 0.00% | – |
| Q4 2017 | $109,000 | +9.0% | 2,744 | +9.5% | 0.00% | – |
| Q3 2017 | $100,000 | -32.4% | 2,505 | -27.2% | 0.00% | – |
| Q2 2017 | $148,000 | +60.9% | 3,441 | +17.7% | 0.00% | – |
| Q1 2017 | $92,000 | +33.3% | 2,924 | +6.9% | 0.00% | – |
| Q4 2016 | $69,000 | 0.0% | 2,734 | -2.4% | 0.00% | – |
| Q3 2016 | $69,000 | +32.7% | 2,802 | +9.9% | 0.00% | – |
| Q2 2016 | $52,000 | +136.4% | 2,549 | +77.3% | 0.00% | – |
| Q1 2016 | $22,000 | -33.3% | 1,438 | -42.1% | 0.00% | – |
| Q4 2015 | $33,000 | -8.3% | 2,484 | -3.0% | 0.00% | – |
| Q3 2015 | $36,000 | – | 2,562 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 426,500 | $11,754,340 | 3.96% |
| ASHFORD CAPITAL MANAGEMENT INC | 916,747 | $25,274,715 | 3.72% |
| ARMISTICE CAPITAL, LLC | 5,092,000 | $140,386,440 | 2.15% |
| S&T BANK/PA | 215,578 | $5,943 | 1.15% |
| Aristotle Capital Boston, LLC | 1,187,981 | $32,752,634 | 1.06% |
| RICE HALL JAMES & ASSOCIATES, LLC | 544,468 | $15,010,983 | 0.95% |
| Tributary Capital Management, LLC | 352,429 | $9,716,468 | 0.92% |
| Bridge City Capital, LLC | 65,297 | $1,800,238 | 0.91% |
| Integral Health Asset Management, LLC | 220,000 | $6,065,400 | 0.84% |
| Retirement Planning Co of New England, Inc. | 51,608 | $1,422,833 | 0.79% |